On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404) announced that its subsidiary, Huasheng Pharmaceutical, has signed a technology transfer contract with Panlong Pharmaceutical. The agreement involves the transfer of technology for “Glucosamine Sulfate Capsules” from Huasheng to Panlong, with a total transfer fee of RMB 4.5 million.
Product Details
The Glucosamine Sulfate Capsules, with a specification of 0.25g, are primarily used for the treatment of primary and secondary osteoarthritis. Huasheng Pharmaceutical has completed all research work related to the contract product and has obtained the acceptance notice for registration application from the National Medical Products Administration, with the acceptance number CYHS2404047.-Fineline Info & Tech
Leave a Reply